Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Nvo save search
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.1%
H: 2.99%
C: 2.18%
snipr001 cancer trials funding
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -5.02%
H: 5.6%
C: 0.96%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 2.6%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: -1.27%
H: 1.68%
C: 0.5%
iph6101 blood trial phase 1 cancer phase 2
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress
Published: 2021-12-09 (Crawled : 11:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.09%
H: 0.32%
C: -0.26%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: 0.2%
H: 1.6%
C: -2.8%
cancer
Global Peptide Cancer Therapeutics Market (2021 to 2026) - Drug Dosage, Price & Clinical Trials Insight
Published: 2021-03-16 (Crawled : 17:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.96%
C: 0.78%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.08%
H: 1.42%
C: 1.23%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 2.42%
H: 1.03%
C: 0.2%
clinical trials cancer drug trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.